C K Stover

Summary

Publications

  1. ncbi request reprint A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 405:962-6. 2000
  2. ncbi request reprint Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis
    D R Sherman
    Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Science 272:1641-3. 1996
  3. ncbi request reprint Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments
    S N Coulter
    PathoGenesis Corporation, 201 Elliott Avenue West, Seattle, WA 98119, USA
    Mol Microbiol 30:393-404. 1998
  4. pmc Reporter gene technology to assess activity of antimycobacterial agents in macrophages
    T M Arain
    Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 40:1542-4. 1996
  5. ncbi request reprint Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 406:959-64. 2000
  6. pmc Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability
    S Westbrock-Wadman
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 43:2975-83. 1999
  7. ncbi request reprint AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis
    D R Sherman
    Laboratory of Tuberculosis and Research Biology, PathoGenesis Corporation, Seattle, WA 98119, USA
    Biofactors 10:211-7. 1999
  8. pmc Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery
    T M Arain
    Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 40:1536-41. 1996
  9. pmc Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare
    R M Shawar
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 41:570-4. 1997
  10. pmc Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis
    G G Mahairas
    Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corp, Seattle, Washington 98119, USA
    J Bacteriol 178:1274-82. 1996

Collaborators

Detail Information

Publications12

  1. ncbi request reprint A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 405:962-6. 2000
    ..tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis...
  2. ncbi request reprint Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis
    D R Sherman
    Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Science 272:1641-3. 1996
    ..To survive during infection, isoniazid-resistant KatG mutants have apparently compensated for the loss of KatG catalase-peroxidase activity by a second mutation, resulting in hyperexpression of AhpC...
  3. ncbi request reprint Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments
    S N Coulter
    PathoGenesis Corporation, 201 Elliott Avenue West, Seattle, WA 98119, USA
    Mol Microbiol 30:393-404. 1998
    ....
  4. pmc Reporter gene technology to assess activity of antimycobacterial agents in macrophages
    T M Arain
    Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 40:1542-4. 1996
    ..This methodology allowed the efficacy of antibiotics against intracellular mycobacteria to be assessed without the labor-intensive procedures and protracted incubation requirements associated with conventional CFU determinations...
  5. ncbi request reprint Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 406:959-64. 2000
    ..We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances...
  6. pmc Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability
    S Westbrock-Wadman
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 43:2975-83. 1999
    ....
  7. ncbi request reprint AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis
    D R Sherman
    Laboratory of Tuberculosis and Research Biology, PathoGenesis Corporation, Seattle, WA 98119, USA
    Biofactors 10:211-7. 1999
    ..We propose that compensatory ahpC promoter mutations are selected from KatG-deficient, isoniazid-resistant M. tuberculosis during infections, to mitigate the added burden imposed by organic peroxides on these strains...
  8. pmc Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery
    T M Arain
    Department of Molecular Microbiology, PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 40:1536-41. 1996
    ..Furthermore, evidence suggests that the BCG-based screen may allow the direct identification of bactericidal agents...
  9. pmc Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare
    R M Shawar
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Antimicrob Agents Chemother 41:570-4. 1997
    ..With this method, it is possible to screen a large number of samples in a short period of time...
  10. pmc Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis
    G G Mahairas
    Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corp, Seattle, Washington 98119, USA
    J Bacteriol 178:1274-82. 1996
    ..These findings may be applicable to the rational design of a new attenuated tuberculosis vaccine and the development of new diagnostic tests to distinguish BCG vaccination from tuberculosis infection...
  11. pmc Disparate responses to oxidative stress in saprophytic and pathogenic mycobacteria
    D R Sherman
    Laboratory of Tuberculosis and Molecular Microbiology, PathoGenesis Corporation, Seattle, WA 98119, USA
    Proc Natl Acad Sci U S A 92:6625-9. 1995
    ..tuberculosis contains numerous deletions and frameshifts and is probably nonfunctional. Apparently the response of pathogenic mycobacteria to oxidative stress differs significantly from the inducible OxyR response of other bacteria...
  12. pmc Identification and characterization of the PutP proline permease that contributes to in vivo survival of Staphylococcus aureus in animal models
    W R Schwan
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Infect Immun 66:567-72. 1998
    ..aureus high-affinity proline permease suggests that proline scavenging by the bacteria is important for in vivo growth and proliferation and that analogs of proline may serve as potential antistaphylococcal therapeutic agents...